Literature DB >> 25117245

Live-cell imaging of human pluripotent stem cells by a novel lectin probe rBC2LCN.

Hiroaki Tateno1, Yasuko Onuma, Yuzuru Ito.   

Abstract

We performed comprehensive glycome analysis of a large set of human pluripotent stem cells (hPSCs) using a high-density lectin microarray. We found that a recombinant lectin, rBC2LCN, binds exclusively to all of the undifferentiated hPSCs tested, but not to differentiated somatic cells. rBC2LCN can be used for both the staining and sorting of fixed and live hPSCs. rBC2LCN could serve as a novel detection reagent for hPSCs, particularly given that rBC2LCN is cost effective and, unlike conventional antibodies which require mammalian cells for their production, is easy to produce in a large amount (0.1 g/L) in an Escherichia coli expression system. Here we describe protocols for the fluorescence staining of fixed and live hPSCs and their detection by flow cytometry.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117245     DOI: 10.1007/978-1-4939-1292-6_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Technical approaches to induce selective cell death of pluripotent stem cells.

Authors:  Ho-Chang Jeong; Seung-Ju Cho; Mi-Ok Lee; Hyuk-Jin Cha
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

2.  Carcinoma-associated fucosylated antigens are markers of the epithelial state and can contribute to cell adhesion through CLEC17A (Prolectin).

Authors:  Adrien Breiman; María Dolores López Robles; Sophie de Carné Trécesson; Klara Echasserieau; Karine Bernardeau; Kurt Drickamer; Anne Imberty; Sophie Barillé-Nion; Frédéric Altare; Jacques Le Pendu
Journal:  Oncotarget       Date:  2016-03-22

3.  rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma.

Authors:  Shuuji Mawaribuchi; Yoshikazu Haramoto; Hiroaki Tateno; Yasuko Onuma; Yasuhiko Aiki; Yuzuru Ito
Journal:  FEBS Open Bio       Date:  2020-05-05       Impact factor: 2.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.